



OPEN

## Pancancer survival analysis of cancer hallmark genes

Ádám Nagy<sup>1,2</sup>, Gyöngyi Munkácsy<sup>1</sup> & Balázs Győrffy<sup>1,2✉</sup>

Cancer hallmark genes are responsible for the most essential phenotypic characteristics of malignant transformation and progression. In this study, our aim was to estimate the prognostic effect of the established cancer hallmark genes in multiple distinct cancer types. RNA-seq HTSeq counts and survival data from 26 different tumor types were acquired from the TCGA repository. DESeq was used for normalization. Correlations between gene expression and survival were computed using the Cox proportional hazards regression and by plotting Kaplan–Meier survival plots. The false discovery rate was calculated to correct for multiple hypothesis testing. Signatures based on genes involved in genome instability and invasion reached significance in most individual cancer types. Thyroid and glioblastoma were independent of hallmark genes (61 and 54 genes significant, respectively), while renal clear cell cancer and low grade gliomas harbored the most prognostic changes (403 and 419 genes significant, respectively). The eight genes with the highest significance included BRCA1 (genome instability, HR 4.26,  $p < 1E-16$ ), RUNX1 (sustaining proliferative signaling, HR 2.96,  $p = 3.1E-10$ ) and SERPINE1 (inducing angiogenesis, HR 3.36,  $p = 1.5E-12$ ) in low grade glioma, CDK1 (cell death resistance, HR = 5.67,  $p = 2.1E-10$ ) in kidney papillary carcinoma, E2F1 (tumor suppressor, HR 0.38,  $p = 2.4E-05$ ) and EREG (enabling replicative immortality, HR 3.23,  $p = 2.1E-07$ ) in cervical cancer, FBP1 (deregulation of cellular energetics, HR 0.45,  $p = 2.8E-07$ ) in kidney renal clear cell carcinoma and MYC (invasion and metastasis, HR 1.81,  $p = 5.8E-05$ ) in bladder cancer. We observed unexpected heterogeneity and tissue specificity when correlating cancer hallmark genes and survival. These results will help to prioritize future targeted therapy development in different types of solid tumors.

Pancancer projects help to analyze the similarities and differences among different types of cancer by investigating genomic, epigenomic, transcriptomic and proteomic traits of the tumors. A leading effort in the pancancer genomic field is the PanCancer Atlas from the TCGA consortium <sup>1</sup>, which focuses on the transcriptome, on the genomic interactions between somatic drivers and germline mutations, on the links to the methylome, on the proteome and on the tumor microenvironment and their implications for targeted and immune therapies <sup>2</sup>.

During tumorigenesis, normal cells evolve to a neoplastic state in which they share common characteristics, including sustained proliferative signaling, loss of growth suppressors, apoptosis resistance, replicative immortality, angiogenesis induction, invasion and metastasis activation, genomic instability, inflammation, and energy metabolism reprogramming—the so-called “hallmarks of cancer” <sup>3,4</sup>. A comprehensive database of genes associated with diverse cancer hallmarks was recently established, enabling the selection of hallmark-specific genes to be measured in transcriptome-level studies <sup>5</sup>. Altogether, 671 cancer genes were grouped into eight main hallmark categories; notably, some of the genes were linked simultaneously to multiple hallmarks <sup>5</sup>.

Analysis of gene expression contributed to the identification of molecular cancer subtypes capable of characterizing tumors and recognizing their biological characteristics, enabling the development of effectively targeted therapeutics. Single or multigene tests have been introduced to measure the deregulation of specific molecular pathways that can guide therapeutic decision-making by identifying genes that can serve as predictive or prognostic biomarkers. Breast cancer treatment is an outstanding example of a multigene decision tree-based treatment decision support protocol. The decision tree includes human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PgR). The overexpression or amplification of HER2 is present in approximately 25% of breast cancer cases <sup>6</sup>. HER2-overexpressing tumors treated with anti-HER2 (trastuzumab and pertuzumab) therapy have improved disease-free and overall survival <sup>7</sup>. ER-positive tumors are eligible for endocrine therapy <sup>8</sup>. Increased disease-free and overall survival time was obtained by targeting ER with the antiestrogen tamoxifen in breast cancer <sup>9</sup>. PgR positivity helps to improve the identification of ER-positive patients. ER, HER2, and PgR define three molecular subtypes of breast cancer, each with different

<sup>1</sup>Department of Bioinformatics, Semmelweis University, Tüzoltó u. 7-9, 1094 Budapest, Hungary. <sup>2</sup>TTK Momentum Cancer Biomarker Research Group, Budapest, Hungary. ✉email: gyorffy.balazs@med.semmelweis-univ.hu

treatment modalities. Those patients who are negative for all three markers are designated as triple-negative breast cancer; these patients have generally worse prognoses and conversely need a more aggressive systemic therapy.

Establishing prognostic multigene classification protocols can contribute to the understanding of tumor biology and to better prediction of cancer progression and cancer treatment strategies. One important issue is the selection of the proper method for the combination of the genes. First, genes can be utilized independently in a decision tree, where each node can be based on a single gene. Second, when multiple genes are combined, the most widespread approach is to compute their mean expression and to use this new value as a surrogate for the activity of the entire signature. A third option is to combine multiple genes after assigning a different weight to each of them. With breast cancer as an example, such combined signatures are utilized in FDA-approved multi-gene signature platforms, including the 76-gene signature, 21-gene signature and 70-gene signature platforms; all three of these can predict the prognosis of cancer under different conditions<sup>10–12</sup>.

In this study, our goal was to rank established cancer hallmark genes according to their correlation to survival in a large cohort of distinct cancer types. We also aimed to correlate the relevance of each cancer hallmark in each of the available tumor types by assessing the prognostic power of signatures comprising hallmark genes.

## Results

**Transcriptomic database.** The complete dataset of RNA-seq samples with follow-up comprised 9663 specimens from 26 distinct tumor types with breast cancer as the largest ( $n=1090$ ) and thymoma as the smallest set ( $n=118$ ). Across the entire database, the median follow-up for overall survival (OS) was 24.3 months, and for relapse-free survival (RFS), it was 23.8 months. Most datasets contained both OS and RFS data, with the exception of AML, glioblastoma, melanoma and thymoma, which only had RFS data. Ovarian cancer patients had the highest median OS, while gastric and head and neck cancer patients had the shortest OS (Fig. 1C). In addition, glioma and liver cancer patients had the longest and the shortest median RFS at 23.8 and 6.7 months, respectively (Fig. 1C).

Clinico-pathological characteristics of patients, including stage, grade, sex and race, were available for 6301, 4126, 9720 and 9471 patients, respectively (Table 1). According to the stage, head and neck cancer had the most patients in stage 4, and testicular cancer had the most patients in stage 0 or stage 1. The proportion of patients by tumor grade indicates that an unfavorable high grade was more common in bladder cancer, while a favorable low grade was restricted to head and neck cancer. Sex and ethnicity data of the patients showed that the number of males with cancer is higher than the number of females with cancer and that Caucasians give the majority in the TCGA database (Table 1).


**The strongest cutoff value in the survival analysis.** We demonstrate the calculation of the best cutoff via the CDK1 gene in kidney papillary carcinoma and ovarian cancer in Fig. 1A,B. To validate the robustness of CDK1 expression in kidney papillary carcinoma, we performed multivariate survival analysis for OS using the somatic mutation data of 278 renal cancer patients including CDK1 expression and the mutations of the top five mutated genes. These include MET (proportion of patient samples with a mutation in kidney renal papillary carcinomas: 24%), MUC16 (20%), KMT2C (19%), SETD2 (17%) and FAT1 (15%). In the multivariate survival analysis, we found that the association between the CDK1 expression retained its significance ( $p=1.55E-07$ ) when including the mutation status of MET ( $p=0.952$ ), MUC16 ( $p=5.65E-01$ ), KMT2C ( $p=0.909$ ), SETD2 ( $p=0.04$ ) and FAT1 ( $p=0.948$ ) genes.

**Prognostic significance of hallmark-associated genes across 26 types of cancer.** Cox regression analysis was performed using the RNA-seq expression of 671 cancer hallmark genes. The results of survival analysis across 26 types of cancer for each gene are listed in Supplemental Table S1. We computed the proportion of significant genes in each hallmark and in each tumor type (Fig. 2). Hierarchical clustering was performed to correlate different tumor types and cancer hallmark-associated genes. In this analysis, genes associated with invasion and metastasis activation, genome instability, sustained proliferative signaling and cellular energetics deregulation clustered into separate cohorts (Fig. 2). The top five tumors that contained the highest proportion of established cancer hallmark genes significantly associated with overall survival were kidney renal clear cell carcinoma, low grade glioma, melanoma, thymoma, and liver cancer.

**Hallmark signatures and survival in different types of tumors.** The expression signature of hallmark features was determined for each sample, and the prognostic effect of these signatures was investigated in different types of cancer. Significant  $p$  values ( $p<0.05$ ) are illustrated as forest plots in Fig. 3A.

Of the eight hallmark feature signatures, seven showed a significant association with OS in low grade glioma. On the other hand, lung squamous carcinoma, uterine, ovarian, sarcoma, bladder and esophageal cancer contained only one significant hallmark signature (Fig. 3B).

Tumor mutation burden was also determined, and it showed a significant association with OS in glioma (HR 3.25,  $p=6.3E-11$ ), melanoma (HR 0.41,  $p=6.5E-10$ ), bladder cancer (HR 0.49,  $p=5.6E-06$ ), uterine cancer (HR 0.33,  $p=2.5E-05$ ), ovarian cancer (HR 0.69,  $p=3.8E-03$ ), stomach cancer (HR = 0.62,  $p=4.2E-03$ ) and kidney renal clear cell carcinoma (HR 2.26,  $p=2.0E-04$ ) (Fig. 3C). To demonstrate the reliability of these results, we selected breast cancer and performed univariate survival analysis for the significant cancer hallmark signatures using an independent gene expression dataset of 1976 samples obtained from the METABRIC study<sup>13</sup>. Of the four cancer hallmark signatures significant in the TCGA dataset, three were also significant in the METABRIC (sustaining proliferative signaling: HR 0.83,  $p=2.55E-03$ , CI 0.74–0.94; inducing angiogenesis: HR 0.77,  $p=2.13E-05$ , CI 0.69–0.87; deregulation of cellular energetics: HR 1.23,  $p=2.98E-03$ , CI 1.07–1.41) showing high reproducibility of the overall analysis pipeline (Fig. 3B).



**Figure 1.** Overview of cutoff determination and survival distribution in the database. The determination of the best cutoff value in the survival analysis demonstrated with the CDK1 gene in kidney papillary carcinoma (A) and ovarian cancer (B). Survival time characteristics of tumors with observed events (C).

In multivariate analysis of OS, including the expression signature of hallmark features, sex, race, tumor stage, tumor grade and age, most of the signatures retained their significance (Table 2).

**Genes with the greatest prognostic power in multiple tumor types.** In at least ten tumor types, there were 39 genes whose expression was associated with OS (Fig. 4A). We pinpointed the genes with the highest prognostic power in each cancer hallmark feature: BRCA1 associated with genome instability in low grade glioma ( $HR = 4.26, p < 1E-16$ ), CDK1 linked to cell death resistance in kidney papillary carcinoma ( $HR = 5.67, p = 2.1E-10$ ), the E2F1 tumor suppressor in cervical cancer ( $HR = 0.38, p = 2.4E-05$ ), EREG enabling replicative immortality in cervical cancer ( $HR = 3.23, p = 2.1E-07$ ), FBP1 participating in the deregulation of cellular energetics in kidney renal clear cell carcinoma ( $HR = 0.45, p = 2.8E-07$ ), MYC activating invasion and metastasis in blad-

Tumor type	TCGA code	Samples with RNA-seq data	Median survival-OS (months)	Events (n)	Median survival time in patients with an OS event	Median survival-RFS (months)	Events (n)	Median survival in patients with a relapse (months)	Sex (F/M)	Stage (S0/S1/S2/S3/S4)	Grade (low/high)	Race (White/Asian/Black-African)
AML	LAML	151	10.13	97	7.13	0.00	0	–	68/83	–	–	135/1/13
Bladder	BLCA	405	17.87	179	13.60	0.00	31	15.40	106/299	0/2/130/138/133	21/381	321/44/23
Breast	BRCA	1090	28.10	151	42.40	21.35	84	25.77	1078/12	0/181/619/247/20	–	752/61/182
Cervical	CESC	304	21.23	71	20.23	12.75	26	16.10	304/0	–	153/119	209/20/30
Colon	COAD	454	22.30	102	13.47	0.00	23	16.87	214/240	0/75/176/128/64	–	212/11/59
Esophagus	ESCA	161	13.57	64	13.38	0.00	21	7.47	23/138	0/16/69/49/8	82/44	100/38/5
Glioblastoma	GBM	153	11.90	122	12.70	0.00	1	51.67	54/99	–	–	137/5/10
Glioma	LGG	510	22.12	125	27.13	0.00	20	19.93	228/282	–	248/261	470/8/21
Head and neck	HNSC	500	21.27	217	14.33	0.00	28	7.70	133/367	0/25/70/78/259	360/121	426/10/47
Kidney (clear cell)	KIRC	530	39.85	173	27.30	0.00	15	30.00	186/344	0/265/57/123/82	241/281	459/8/56
Kidney (papillary)	KIRP	288	25.58	44	21.37	13.22	28	15.72	76/212	0/172/21/51/15	–	205/6/60
Liver	LIHC	371	19.57	130	13.85	10.73	143	9.10	121/250	0/171/86/85/5	232/134	184/158/17
Lung (adeno)	LUAD	513	21.13	187	19.93	9.80	89	15.90	276/237	0/274/121/84/26	–	387/7/52
Lung (squamous)	LUSC	501	21.63	216	17.85	11.83	61	18.40	130/371	0/244/162/84/7	–	349/9/30
Melanoma	SKCM	468	34.45	215	35.67	0.00	0	–	179/289	7/76/140/170/23	–	445/12/1
Ovary	OV	374	34.03	230	36.55	0.00	126	17.67	374/0	–	43/321	324/11/25
Pancreas	PAAD	177	15.43	92	12.90	0.00	23	14.97	80/97	0/21/146/3/4	125/50	156/11/6
Paraganglioma	PCPG	178	25.08	6	15.08	20.42	4	27.65	101/77	–	–	147/6/20
Prostate	PRAD	495	30.80	10	36.73	20.53	30	25.30	0/495	–	–	147/2/7
Rectum	READ	165	20.33	25	20.33	0.00	6	28.68	75/90	0/30/51/51/24	–	80/1/6
Sarcoma	SARC	259	31.57	98	22.27	5.37	66	11.17	141/118	–	–	226/6/18
Stomach	STAD	375	14.23	147	11.60	6.60	37	10.50	134/241	0/53/111/150/38	147/219	238/74/11
Testis	TGCT	134	42.03	4	18.85	20.67	27	15.03	0/134	0/55/12/14/0	–	119/4/6
Thymoma	THYM	119	38.83	9	28.43	0.00	0	–	57/62	–	–	99/12/6
Thyroid	THCA	502	31.47	16	34.03	18.72	26	16.43	367/135	0/281/52/112/55	–	332/51/27
Uterine	UCEC	543	30.37	91	23.63	21.03	57	17.33	543/0	–	218/325	372/20/106
Σ	–	9720	24.33	2821	19.23	23.8	972	15.6	5048/4672	7/1941/2023/1567/763	1870/2256	7031/596/844

**Table 1.** Clinical characteristics of patients.


der cancer (HR 1.81,  $p=5.8E-05$ ), RUNX1 sustaining proliferative signaling in glioma (HR 2.96,  $p=3.1E-10$ ) and SERPINE1 playing a role in inducing angiogenesis in glioma (HR 3.36,  $p=1.5E-12$ ) (Fig. 4B-I).

In addition, multivariate Cox regression analysis was also performed using the expression of the 39 most significant genes and the available clinical variables, including race, sex, age, tumor stage and tumor grade. Of the clinical parameters, age and tumor stage were the variables that reached significance in the Cox model in most tumors (for detailed results, see Supplemental Table S2).

**Gene set enrichment analysis.** In glioma, the expression of BRCA1, RUNX1, and SERPINE1 were analyzed using GSEA. High expression of BRCA1 was associated with the enrichment of cell cycle checkpoint genes ( $p<1E-16$ ) and DNA repair genes ( $p=0.038$ ) that have important role in genome instability. High expression of RUNX1 was associated with several proliferation signaling genes such as JAK-STAT ( $p<1E-16$ ), KRAS ( $p<1E-16$ ) and TGFB ( $p=0.007$ ) signaling genes. In patients with high expression of SERPINE1 angiogenesis associated genes ( $p=0.02$ ), apoptosis genes ( $p<1E-16$ ) and hypoxia related genes ( $p<1E-16$ ) were overrepresented.

In cervical cancer, the high expression of E2F1 was associated with the enrichment of tumor suppressor genes such as E2F signaling pathway genes ( $p=0.002$ ) and the high expression of EREG was associated with TGF-beta ( $p<1E-16$ ) signaling pathway genes.

In renal papillary carcinoma, the high expression CDK1 was associated with the enrichment of apoptosis genes ( $p=0.025$ ). In renal clear cell cancer the high expression of FBP1 gene was associated with enrichment of metabolic genes such as fatty acid metabolism ( $p<1E-16$ ), reactive oxygen species pathway ( $p=0.015$ ), and



**Figure 2.** The prognostic power of cancer hallmark genes.

bile acid metabolism ( $p = 0.002$ ). In bladder cancer, the high expression of MYC was associated with metastasis related genes that takes role in apical junction ( $p = 0.002$ ) and MYC signaling pathway genes ( $p = 0.008$ ).

Overall, the GSEA identified cancer hallmark gene sets are in line with our previous results.

## Discussion

In this study, we examined the prognostic significance of previously established cancer hallmark genes<sup>5</sup>. For the survival analysis, we utilized an RNA-seq database from the TCGA that contains 9720 patients of 26 tumor types with clinical annotations. Kidney renal clear cell carcinoma, low grade glioma and melanoma had the highest proportion of cancer hallmark genes that correlated with survival. Hierarchical clustering analysis showed that some cancer hallmark genes clustered together, such as those involved with invasion and metastasis activation, genome instability, sustained proliferative signaling and cellular energetics deregulation (distance was based on the percentage of significant genes per hallmark in each tumor type).

A transcriptomic surrogate signature for each hallmark was also determined; this is based on the means of the average expression of the cancer genes associated with the given hallmark. The prognostic significance of these factors was examined in different types of cancers. Among the eight main hallmark signatures, those associated with oncogene activation, genome instability, cellular energetics, invasion and metastasis and cell death resistance were significant in at least five tumor types.










It is important to mention that in this analysis we did not simply averaged genes whose overexpression worsens the prognosis and those whose loss worsens prognosis. Rather, we use a pre-selected set of genes linked to a single cancer hallmark. Therefore, not the mean of the genes but their relative change influences the final classification. Within a single hallmark, we do not expect to have a perfect negative or positive correlation between the genes, and their mean will be representative for the overall activity of the hallmark.

This approach is supported by the observation that many genes have inverse expression patterns—a negative correlation in terms absolute gene expression levels. For example, for CDKN2A and CCND1 this was observed in multiple studies<sup>14–17</sup>. In case of a negative correlation, exactly those genes should be combined for which





A.



**Figure 4.** Best performing genes in at least 10 distinct tumor types.

cancer types were also uncovered. These results help to prioritize targeting the most relevant hallmark for drug development in each tumor type.

## Methods

**Database setup.** All data processing steps and statistical analyses were performed in the R v3.5.2 statistical environment (<http://www.r-project.org>). The source code are available at GitHub: [https://github.com/adam-nagy91/pancancer\\_survival\\_analysis](https://github.com/adam-nagy91/pancancer_survival_analysis). RNA sequencing (RNA-seq) data were utilized from the Cancer Genome Atlas (TCGA, <https://cancergenome.nih.gov/>). Only tumor types with more than 100 cancer specimens were included to ensure a robust sample number in each analysis.

The RNA-seq HTSeq count data generated by the Illumina HiSeq 2000 RNA Sequencing Version 2 platform were used in the expression analyses. The “DESeq” package based on the negative binomial distribution was used to normalize the raw count data<sup>36</sup>. The Bioconductor “AnnotationDbi” package (<http://bioconductor.org/packages/AnnotationDbi/>) was applied to annotate Ensembl transcript IDs with gene symbols (n = 25,228). A second scaling normalization was performed to set the mean expression of all genes in each patient sample to 1000 to reduce batch effects.

For each sample, the preprocessed and annotated Mutation Annotation Format (MAF) data files that were generated by using MuTect2 for variant detection were used to compute the tumor mutation burden. The “maftools” package (<http://bioconductor.org/packages/maftools/>) was used for the aggregation and visualization of mutation data.

**Defining cancer hallmark signatures.** Altogether, 671 cancer genes were grouped into eight hallmarks<sup>4</sup>, based on gene assignment to hallmarks as described previously<sup>5</sup>. The surrogate hallmark expression signature was calculated by computing the mean expression of all genes associated with the given hallmark in each tumor sample.

**Survival analysis and calculation of the strongest cutoff.** Cox proportional hazards regression analysis was performed to examine the correlation between gene expression and overall survival (OS). The “survival” R package v2.38 (<http://CRAN.R-project.org/package=survival/>) was utilized to calculate log-rank P values, hazard ratios (HR) and 95% confidence intervals (CI). In addition, the survival differences were visualized by generating Kaplan–Meier survival plots.

To maximize the sensitivity of the analysis and to uncover any potential correlation to survival independent of a preset cutoff value (e.g., median), we computed each possible cutoff between the lower and upper quartiles of expression. Then, each of these cutoff values was used in a separate Cox regression analysis. The false discovery rate (FDR) was computed to correct for multiple hypothesis testing, and the result was only accepted as significant in the case of FDR < 10%. The best performing cutoff with the lowest *p* value was used in the final analysis when drawing the Kaplan–Meier plot.

In addition, multivariate survival analysis was performed for the gene expression and clinical features to assess independence from known epidemiological and clinical variables, including race, sex, age, tumor stage and tumor grade.

**Data visualization.** Hierarchical clustering was applied to group and to visualize the survival-associated cancer hallmark genes in different types of cancer using the Genesis software<sup>37</sup>. The “forestplot” R package (<https://CRAN.R-project.org/package=forestplot>) was used to examine the association of cancer hallmark gene signatures with OS across different types of cancer. The “survplot” R package (<http://www.cbs.dtu.dk/~eklund/survplot/>) was used to generate the Kaplan–Meier plots.

**Gene set enrichment analysis (GSEA).** Gene set enrichment analysis (GSEA)<sup>38</sup> was performed for the most significant cancer hallmark genes (Fig. 4B–I). Patients were divided into high and low expression groups based on the expression of the selected gene across all patients within each tumor type. To categorize patients into two groups, we used the same cutoff point also used in the survival analysis. These categories were to designate the “phenotype labels” in the gene set enrichment analysis. The normalized RNA-seq expression and the built in “hallmark cancer genes” sets were used as expression datasets and gene set database, respectively.

## Data availability

TCGA (The Cancer Genome Atlas) dataset is available using the following link: <https://portal.gdc.cancer.gov/>.

Received: 13 November 2020; Accepted: 15 February 2021

Published online: 15 March 2021

## References

- Cooper, L. A. *et al.* PanCancer insights from the cancer genome atlas: The pathologist’s perspective. *J. Pathol.* **244**, 512–524. <https://doi.org/10.1002/path.5028> (2018).
- Ding, L. *et al.* Perspective on oncogenic processes at the end of the beginning of Cancer genomics. *Cell* **173**, 305–320. <https://doi.org/10.1016/j.cell.2018.03.033> (2018).
- Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. *Cell* **100**, 57–70 (2000).
- Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: The next generation. *Cell* **144**, 646–674. <https://doi.org/10.1016/j.cell.2011.02.013> (2011).
- Menyhart, O. *et al.* Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. *Biochem. Biophys. Acta* **300–319**, 2016. <https://doi.org/10.1016/j.bbcan.2016.10.002> (1866).
- Piccart-Gebhart, M. J. *et al.* Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. *N. Engl. J. Med.* **353**, 1659–1672. <https://doi.org/10.1056/NEJMoa052306> (2005).
- Romond, E. H. *et al.* Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. *N. Engl. J. Med.* **353**, 1673–1684. <https://doi.org/10.1056/NEJMoa052122> (2005).
- Fisher, B. *et al.* Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. *J. Clin. Oncol.* **1**, 227–241. <https://doi.org/10.1200/JCO.1983.1.4.227> (1983).
- Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet* **351**, 1451–1467 (1998).
- Weigelt, B. *et al.* Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. *Can. Res.* **65**, 9155–9158. <https://doi.org/10.1158/0008-5472.CAN-05-2553> (2005).
- Wang, Y. *et al.* Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. *Lancet* **365**, 671–679. [https://doi.org/10.1016/S0140-6736\(05\)17947-1](https://doi.org/10.1016/S0140-6736(05)17947-1) (2005).
- Sparano, J. A. & Paik, S. Development of the 21-gene assay and its application in clinical practice and clinical trials. *J. Clin. Oncol.* **26**, 721–728. <https://doi.org/10.1200/JCO.2007.15.1068> (2008).
- Curtis, C. *et al.* The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. *Nature* **486**, 346–352. <https://doi.org/10.1038/nature10983> (2012).
- Fu, Z. J. *et al.* Overexpression of CyclinD1 and underexpression of p16 correlate with lymph node metastases in laryngeal squamous cell carcinoma in Chinese patients. *Clin. Exp. Metast.* **25**, 887–892. <https://doi.org/10.1007/s10585-008-9207-x> (2008).
- Nosho, K. *et al.* Cyclin D1 is frequently overexpressed in microsatellite unstable colorectal cancer, independent of CpG island methylator phenotype. *Histopathology* **53**, 588–598. <https://doi.org/10.1111/j.1365-2559.2008.03161.x> (2008).
- Stein, G. H., Drullinger, L. F., Soulard, A. & Dulic, V. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. *Mol. Cell Biol.* **19**, 2109–2117. <https://doi.org/10.1128/mcb.19.3.2109> (1999).
- Zhao, X., Song, T., He, Z., Tang, L. & Zhu, Y. A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. *Med. Oncol.* **27**, 985–991. <https://doi.org/10.1007/s12032-009-9320-y> (2010).
- Zainuddin, A., Chua, K. H., Tan, J. K., Jaafar, F. & Makpol, S. gamma-Tocotrienol prevents cell cycle arrest in aged human fibroblast cells through p16(INK4a) pathway. *J. Physiol. Biochem.* **73**, 59–65. <https://doi.org/10.1007/s13105-016-0524-2> (2017).
- Miller, D. M., Thomas, S. D., Islam, A., Muench, D. & Sedoris, K. c-Myc and cancer metabolism. *Clin. Cancer Res.* **18**, 5546–5553. <https://doi.org/10.1158/1078-0432.CCR-12-0977> (2012).
- Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. *Oncogene* **19**, 6102–6114. <https://doi.org/10.1038/sj.onc.1203973> (2000).
- Sebio, A., Kahn, M. & Lenz, H. J. The potential of targeting Wnt/beta-catenin in colon cancer. *Expert Opin. Ther. Targets* **18**, 611–615. <https://doi.org/10.1517/14728222.2014.906580> (2014).
- Sarbia, M. *et al.* Prognostic significance of cyclin D1 in esophageal squamous cell carcinoma patients treated with surgery alone or combined therapy modalities. *Int. J. Cancer* **84**, 86–91. [https://doi.org/10.1002/\(sici\)1097-0215\(19990219\)84:1%3c86::aid-ijc16%3e3.0.co;2-7](https://doi.org/10.1002/(sici)1097-0215(19990219)84:1%3c86::aid-ijc16%3e3.0.co;2-7) (1999).

23. Carter, S. L., Eklund, A. C., Kohane, I. S., Harris, L. N. & Szallasi, Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. *Nat. Genet.* **38**, 1043–1048. <https://doi.org/10.1038/ng1861> (2006).
24. Habermann, J. K. *et al.* The gene expression signature of genomic instability in breast cancer is an independent predictor of clinical outcome. *Int. J. Cancer* **124**, 1552–1564. <https://doi.org/10.1002/ijc.24017> (2009).
25. Furuta, E., Okuda, H., Kobayashi, A. & Watabe, K. Metabolic genes in cancer: Their roles in tumor progression and clinical implications. *Biochem. Biophys. Acta.* **141**–152, 2010. <https://doi.org/10.1016/j.bbcan.2010.01.005> (1805).
26. Alo, P. L. *et al.* Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. *Cancer* **77**, 474–482. [https://doi.org/10.1002/\(SICI\)1097-0142\(19960201\)77:3%3c474::AID-CNCR8%3e3.0.CO;2-K](https://doi.org/10.1002/(SICI)1097-0142(19960201)77:3%3c474::AID-CNCR8%3e3.0.CO;2-K) (1996).
27. Kusakabe, T., Nashimoto, A., Honma, K. & Suzuki, T. Fatty acid synthase is highly expressed in carcinoma, adenoma and in regenerative epithelium and intestinal metaplasia of the stomach. *Histopathology* **40**, 71–79 (2002).
28. Bandyopadhyay, S. *et al.* FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. *Oncogene* **24**, 5389–5395. <https://doi.org/10.1038/sj.onc.1208555> (2005).
29. Espinoza, I. & Miele, L. Notch inhibitors for cancer treatment. *Pharmacol. Ther.* **139**, 95–110. <https://doi.org/10.1016/j.pharmthera.2013.02.003> (2013).
30. Zheng, X. *et al.* Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. *Nature* **527**, 525–530. <https://doi.org/10.1038/nature16064> (2015).
31. Igney, F. H. & Krammer, P. H. Death and anti-death: Tumour resistance to apoptosis. *Nat. Rev. Cancer* **2**, 277–288. <https://doi.org/10.1038/nrc776> (2002).
32. Holleman, A. *et al.* The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. *Blood* **107**, 769–776. <https://doi.org/10.1182/blood-2005-07-2930> (2006).
33. Jourdan, M. *et al.* Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. *Br. J. Haematol.* **145**, 45–58. <https://doi.org/10.1111/j.1365-2141.2008.07562.x> (2009).
34. Hofmann, W. K. *et al.* Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. *Blood* **98**, 787–794 (2001).
35. Vallat, L. *et al.* The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. *Blood* **101**, 4598–4606. <https://doi.org/10.1182/blood-2002-06-1743> (2003).
36. Anders, S. & Huber, W. Differential expression analysis for sequence count data. *Genome Biol.* **11**, R106. <https://doi.org/10.1186/gb-2010-11-10-r106> (2010).
37. Sturm, A., Quackenbush, J. & Trajanoski, Z. Genesis: Cluster analysis of microarray data. *Bioinformatics* **18**, 207–208 (2002).
38. Subramanian, A. *et al.* Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550. <https://doi.org/10.1073/pnas.0506580102> (2005).

## Acknowledgements

The research was financed by the 2018-2.1.17-TET-KR-00001 and 2018-1.3.1-VKE-2018-00032 grants and by the Higher Education Institutional Excellence Programme (2020-4.1.1.-TKP2020) of the Ministry for Innovation and Technology in Hungary, within the framework of the Bionic thematic programme of the Semmelweis University. This study was also supported by the ÚNKP-19-3-IV-SE-5 New National Excellence Program of the Ministry for Innovation and Technology. The authors acknowledge the support of ELIXIR Hungary ([www.elixir-hungary.org](http://www.elixir-hungary.org)).

## Author contributions

B.G. contributed to the conception, design and writing of the manuscript. G.M. contributed to the data interpretation and drafting the manuscript. Á.N. contributed to the data analysis, data interpretation and drafting the manuscript. All of the authors read and approved the final manuscript.

## Competing interests

The authors declare no competing interests.

## Additional information

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-84787-5>.

**Correspondence** and requests for materials should be addressed to B.G.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021